Wedbush Has Optimistic Outlook of Disc Medicine Q3 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Wedbush raised their Q3 2025 earnings estimates for Disc Medicine in a research report issued to clients and investors on Wednesday, October 22nd. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.49) per share for the quarter, up from their prior estimate of ($1.65). Wedbush currently has a “Outperform” rating and a $110.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s Q4 2025 earnings at ($1.40) EPS, FY2025 earnings at ($5.52) EPS, Q1 2026 earnings at ($1.43) EPS, Q2 2026 earnings at ($1.37) EPS, Q3 2026 earnings at ($1.27) EPS, Q4 2026 earnings at ($1.14) EPS, FY2026 earnings at ($5.20) EPS, FY2027 earnings at ($2.46) EPS and FY2029 earnings at $8.39 EPS.

IRON has been the topic of a number of other reports. National Bankshares set a $153.00 target price on shares of Disc Medicine in a report on Friday, October 17th. Morgan Stanley increased their price objective on shares of Disc Medicine from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, August 18th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Thursday, July 3rd. Raymond James Financial increased their price objective on shares of Disc Medicine from $89.00 to $108.00 and gave the stock a “strong-buy” rating in a report on Friday, October 17th. Finally, Cantor Fitzgerald increased their price objective on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and an average price target of $110.70.

Disc Medicine Stock Up 4.7%

Shares of NASDAQ:IRON opened at $89.65 on Monday. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of -20.06 and a beta of 0.80. Disc Medicine has a 1-year low of $30.82 and a 1-year high of $95.95. The company’s fifty day moving average is $66.92 and its two-hundred day moving average is $56.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.11 and a current ratio of 32.11.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.41).

Insider Buying and Selling

In other Disc Medicine news, Director Kevin Bitterman sold 71,961 shares of the firm’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $70.58, for a total transaction of $5,079,007.38. Following the transaction, the director owned 500,621 shares of the company’s stock, valued at approximately $35,333,830.18. This trade represents a 12.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 226,933 shares of company stock worth $17,005,801. 3.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Disc Medicine

Large investors have recently bought and sold shares of the stock. Amalgamated Bank increased its stake in Disc Medicine by 38.6% during the 1st quarter. Amalgamated Bank now owns 787 shares of the company’s stock valued at $39,000 after buying an additional 219 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of Disc Medicine by 13,428.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 947 shares of the company’s stock worth $47,000 after purchasing an additional 940 shares during the last quarter. CWM LLC grew its stake in shares of Disc Medicine by 213.5% in the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after purchasing an additional 711 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Disc Medicine in the 2nd quarter worth approximately $57,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Disc Medicine by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock worth $71,000 after purchasing an additional 181 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.